Browse drugs

…through CMR. Based on recent evidence, combination therapy with rituximab (RTX, 2 x 1000 mg with a two-week gap and a repeat dose after s…

…e most prescribed IS in ACA- (47%), mainly for ILD (82%), while methotrexate (MTX) predominated in ACA+ (53%), used for cutaneous (44%) or a…

…nation treatment with mycophenolate and rituximab (MMF-RTX) vs. rituximab monotherapy (RTX) in a single-center cohort of patients affecte…

…ose receiving cyclophosphamide (CYC) and 20% of those receiving mycophenolate mofetil (MMF) achieved a renal response after 24 weeks. There were no s…

…d HCQ 400 mg/day. In August 2025, due to inadequate efficacy of rituximab (3 g), intolerance to MMF, and limitations on IS (due to leukop…

…ntenance in 69% of cases, a total of 14.5% of patients received rituximab as a rescue therapy, while 20.3% were treated with CYC as a rei…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

… a shift from oxidative to glycolytic metabolism.In conclusion, fumarate derivatives activate key Nrf2-dependent antioxidant pathways and reveal a n…

…tion of potential offending agents such as MMF, fluoxetine, and hydroxychloroquine, and treatment with oral nimodipine, she developed a new left h…

…onths. Most common medication exposure (ever) were MMF (58.5%), prednisone (44.5%), HCQ (34.7%), MTX (29.5%), IVIg (13.6%), and cyclophosp…

…n their ILD by 24 months. Sixty-nine (93.2%) were on IS (mainly MMF) at time of HRCTs. Twenty-eight patients (37.8%) presented at l…

…SP was 21mmHg. HRCT Scan confirmed mild ILD.He was commenced on mycophenolate mofetil, amlodipine and omeprazole. Mid-2023 he presented with shortnes…